What is it about?
This study demonstrated CSF profiles of neutral glycolipids, especially glucosylceramide determined by our new assay method employing HILIC-ESI-MS/MS and alos of active complement C5 fragment, C5a with ELISA assay method. The data revealed for the first time that central innate immunity was significantly downregulated and no accumulation of glucosylceramide in PD CSF. We found, however, that significant correlation of certain species of glucosylceramide with CSF C5a. These data strongly suggest that central innate immunity and oligodendrocytes might be involved in PD patients.
Featured Image
Photo by Kristine Wook on Unsplash
Why is it important?
This is the first indication of the impairment of central complement system and of normal glucosylceramide metabolism in CSF from PD patients. Moreover, this study reported glucosylceramide levels in human CSF for the first time.
Perspectives
Central glycosphingolipid metabolism might be closely related to the central immune status of PD patients. Furhter analyses will be highly anticipated.
Professor Tatsuro Mutoh
Department of Neurolgy, Fujita Health University School of Medicine
Read the Original
This page is a summary of: Cerebrospinal Fluid Profiles in Parkinson’s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment, Journal of Parkinson s Disease, February 2021, IOS Press,
DOI: 10.3233/jpd-202310.
You can read the full text:
Contributors
The following have contributed to this page
